NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for MIA PaCa-2 Cells (Pancreatic Carcinoma Cells, CRL-1420)
- Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Effective and robust intracellular delivery
Work in the presence of serum
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
Download PowerPoint presentation for Mia-PaCa-2 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 88% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems MiaPaCa-2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
MIA PaCa-2 Cell Line:
The MIA PaCa-2 cell line was originally established in 1975 using pancreatic tissue which was removed from a 65-year-old Caucasian male patient who suffered from carcinoma. These cells exhibit an attached epithelial cell morphology, along with having floating rounded cells. This cell line was derived by A. Yunis, et al, and has been observed to have a doubling time of ~40 hours. MIA PaCa-2 cells produce plasminogen activator and CSF-I (human colony stimulating factor, subclass I).
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the MIA Paca-2 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in MIA PaCa-2 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into MIA PaCa-2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems manufacturers preoptimized transfection kits for cancer research. Reagents and transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery into liver, pancreas, and kidney tissues), and in vivo biodistribution reagents (PEG-Liposome, Nanoparticle, Lipid, and Polymer-based kits). Optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, and RNA molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6850)
- 1.5 ml (Catalog #6851)
- 8.0 ml (Catalog #7064)